Empagliflozin Impurity II
✓
100 % Datengenauigkeit
Wissenschaftlicher Support rund um die Uhr
⬡
0 % Toleranz bei der Produktqualität

Lagerstandorte

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

Empagliflozin Impurity II

● Auf Lager

Katalog-Nr.::VE006517
CAS-Nr.::N/A
Summenformel::C17H17ClO2
Molare Masse::288.77 g/mol

Zusätzliche Informationen zu Empagliflozin Impurity II

Parent drug

Empagliflozin

IUPAC-Name

(S)-3-(4-(2- Chlorobenzyl)phenoxy)tetrahy drofuran

Synonyme

N/A

SMILES

ClC1=CC=CC=C1CC2=CC=C(O[C@@H]3COCC3)C=C2

InChI

InChI=1S/C17H17ClO2/c18-17-4-2-1-3-14(17)11-13-5-7-15(8-6-13)20-16-9-10-19-12-16/h1-8,16H,9-12H2/t16-/m0/s1

Beschreibung

The compound Empagliflozin Impurity II a thoroughly characterized reference standard that complies with rigorous regulatory guidelines, including those from USP, EMA, JP, and BP. It is ideal for critical applications such as analytical method development, method validation (AMV), and quality control (QC), especially in the production of Empagliflozin. Designed to support both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA), this product delivers the precision required for reliable results. Additionally, it includes a detailed Structure Elucidation Report (SER), ensuring accuracy and dependability for advanced analytical purposes. It is a potent, highly selective, sodium-glucose cotransporter-2(SGLT-2) inhibitor. It is well-tolerated antihyperglycemic for the treatment of type-2 diabetes. It reduces renal reabsorption of glucose.

References

„Frampton, James E. “Empagliflozin: A Review in Type 2 Diabetes.” Drugs, vol. 78, no. 10, June 2018, pp. 1037–48, https://doi.org/10.1007/s40265-018-0937-z. ?Wanner, Christoph, et al. “Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.” New England Journal of Medicine, vol. 375, no. 4, July 2016, pp. 323–34, https://doi.org/10.1056/nejmoa1515920. ?“

Angebot anfordern

„*“ zeigt erforderliche Felder an

Dieses Feld dient zur Validierung und sollte nicht verändert werden.
Products quotation
Name
Url